Laventair Ellipta (Umeclidinium Bromide, Vilanterol)

Umeclidinium bromide blocks muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine‑induced constriction. Vilanterol stimulates β2‑adrenergic receptors, increasing cyclic AMP and relaxing bronchial smooth muscle. Together they produce a synergistic, prolonged bronchodilatory effect that improves airflow and eases breathing in COPD and asthma.

The prescribed dose of Laventair Ellipta is determined by the treating physician based on the patient’s condition, severity, and response to therapy. Typically, the inhaler is used once daily, but the exact number of inhalations and any dose adjustments are set by the healthcare professional.

Safety data for umeclidinium bromide and vilanterol in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Laventair Ellipta, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Laventair Ellipta combines a long‑acting muscarinic antagonist (LAMA) with a long‑acting β2‑agonist (LABA) in a single inhaler, offering dual mechanisms that many single‑agent products lack. Compared with separate LAMA or LABA inhalers, the combination can simplify dosing, improve adherence, and provide greater overall bronchodilation, though individual response varies.

Store the inhaler at ambient temperature below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Keep the device out of reach of children. Do not expose it to extreme heat or freeze it, and avoid storing it in humid environments such as bathrooms.

Laventair Ellipta is a dry‑powder inhaler (Ellipta device). The patient opens the device, inhales forcefully and deeply through the mouth, and holds their breath for a few seconds before exhaling. Proper technique, including a full inhalation and a tight seal around the mouthpiece, is essential for optimal drug delivery.

Serious adverse reactions, though rare, include paradoxical bronchospasm, significant tachycardia or arrhythmias, severe allergic responses such as anaphylaxis, and angioedema. Patients should be instructed to seek immediate medical attention if they experience sudden worsening of breathing, rapid heartbeat, swelling of the face or throat, or any signs of a severe allergic reaction.

Laventair Ellipta should be avoided in individuals with a known hypersensitivity to umeclidinium, vilanterol, or any excipients in the inhaler. It is also contraindicated in patients who have experienced a severe paradoxical bronchospasm with similar medications. Clinicians should assess each patient’s medical history before initiating therapy.